Shared on22 Oct 25
Fair value Decreased 0.73%

Analysts have slightly lowered their fair value estimate for Halozyme Therapeutics, adjusting the target from $76.00 to $75.44 per share. Recent research reflects modest shifts in revenue expectations, cost discipline, and exposure assessments following company updates and external events.

Shared on08 Oct 25
Fair value Increased 6.05%

Analysts have raised Halozyme Therapeutics' fair value estimate to $76.00 from $71.67. They cited improved revenue growth expectations, higher profit margins, and upward earnings guidance for 2025 as key factors behind the revised price target.

Shared on23 Sep 25
Fair value Increased 1.57%

Analysts have raised Halozyme Therapeutics’ price target to $71.67, reflecting upgraded 2025 EPS guidance driven by robust partner revenue growth and disciplined cost management, though near-term upside remains capped by regulatory uncertainty. Analyst Commentary Bullish analysts cite a substantial 20% increase in 2025 EPS guidance since January, driven by expanding partnered product revenue and strict cost control.

Shared on07 Aug 25
Fair value Increased 1.60%

With the consensus analyst price target unchanged at $69.44, Halozyme Therapeutics saw a modest improvement in valuation as its future P/E declined, signaling slightly enhanced earnings expectations. What's in the News Halozyme raised 2025 earnings guidance, expecting total revenue of $1,275–$1,355 million (26–33% growth) and royalty revenue of $825–$860 million (44–51% growth) over 2024.